Drug intelligence / Profile preview

anvirzel

Development stage: Discontinued
Lead developer: Phoenix Biotechnology
Modality: Small Molecules
Administration: Intramuscular, Sublingual

Overview

Anvirzel is an aqueous extract of the plant Nerium oleander that contains cardiac glycosides (primarily oleandrin and oleandrigenin), polysaccharides, triterpenes, and other plant-derived compounds. It has been developed as a potential treatment for cancer and has shown anti-proliferative effects against various cancer cell lines. Studies indicate it may be particularly effective when combined with cisplatin, even at low concentrations.

Brand names: Anvirzel
Other names: Nerium oleander extract

Beyond the preview

Go deeper on anvirzel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anvirzel.

Explore the full profile